J&J/Pharmacyclics' ibrutinib gets extra CHMP tick for IgM cancer
This article was originally published in Scrip
Executive Summary
The European Medicine Agency's scientific advisors group recommended on 22 May that Imbruvica (ibrutinib) should be indicated for the treatment of Waldenstr?m’s macroglobulinaemia (WM), a very rare blood cell cancer characterized by vast overproduction of immunoglobulin M (IgM). The recent approval of ibrutinib in the US, and its imminent approval in Europe not only provide WM patients with first- and second-line treatment options, but also, says one key opinion leader in WM, will provide a focus for more productively organized patient group and physician activity.